Abstract
Purpose :
Pars plana vitrectomy with ILM peel is a technique used to treat macular holes. The currently accepted technique is to use 0.025% Brilliant Blue G (BBG) dye to stain the ILM, but multiple staining attempts are often needed. Concentrations of 0.05% stain the ILM better, reduce the need for multiple staining attempts, and can thus result in shorter surgical times. Visual and anatomical outcomes were evaluated after use of 0.05% BBG in treatment of macular holes.
Methods :
This is a retrospective interventional case study. From Sept. 2014 to July 2017 there were 159 patients identified as having undergone pars plana vitrectomy, 82 of whom were excluded for visually significant pathology including age-related macular degeneration, primary open-angle glaucoma, retinal detachment, retinal tear or other confounding pathology. 25 patients qualified the inclusion and exclusion criteria, and 27 eyes underwent surgical repair for macular hole. Clinical data was collected at baseline, 1, 3, and 6 months post operation. To measure ocular function, best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) using Optical Coherence Tomography (OCT) were assessed.
Results :
Baseline measurements of BCVA, IOP, and CMT were compared to the measurements from each follow-up. The average (standard deviation) baseline BCVA was 58(10) letters, IOP was 16(3), and due to presence of a macular hole there was no baseline data for CMT. 1,3, and 6 months after surgery average CMT was 297(65), 298(81), and 289(61) micrometers respectively. The average BCVA at 1,3, and 6 months was 58(19), 66(14), 67(13) letters respectively with an average change of +6.33 letters post operation. Average IOP measurement for 1,3, and 6 months post operation was 16(5),14(3), and 15(5) mmHg respectively with an average change of -1 mmHg.
Conclusions :
Use of high concentration 0.05% BBG appeared to be safe for surgical treatment of macular holes with 100% success rate of closure and significant improvement in BCVA.
This is a 2021 ARVO Annual Meeting abstract.